Margolin Brain Institute

Fresno, California 93720

0 studies enrolling now · 30 studies all time

What they study most

Alzheimer Disease, Alzheimer's Disease, Dementia, Irritation/Irritant, Mild Cognitive Impairment, Mild to Severe Alzheimer's Disease, Parkinson's Disease

Studies at this site

• Study in Elderly Alzheimer's Patients to Assess Skin Tolerability, Irritation With 3, 7-Day Applications of DTP-System — Completed
• A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab — Completed
• ELND005 in Patients With Mild to Moderate Alzheimer's Disease — Completed
• A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066 — Completed
• ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease — Completed
• The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility — Completed
• A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY) — Completed
• A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease — Completed
• Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients — Stopped early
• A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease — Stopped early
• A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease — Completed
• Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease — Completed
• A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment — Completed
• A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease — Stopped early
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier) — Completed
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier) — Completed
• An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type — Completed
• Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 — Completed
• Safety and Efficacy Study of AC-3933 in Adults With Mild to Moderate Alzheimer's Disease — Completed
• Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations — Completed
• Effects of ONO-2506PO in Patients With Alzheimer's Disease — Completed
• The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease — Completed
• Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy. — Completed
• Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients — Completed
• Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study — Completed
• SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD) — Completed
• Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD) — Completed
• 18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type — Completed
• ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301) — Completed
• Evaluation of 3APS in Patients With Mild to Moderate Alzheimer's Disease — Status unconfirmed